These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7718885)

  • 21. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.
    Tian ZG; Longo DL; Funakoshi S; Asai O; Ferris DK; Widmer M; Murphy WJ
    Cancer Res; 1995 Nov; 55(22):5335-41. PubMed ID: 7585597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
    Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
    J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
    Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
    Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S; Sforzini S; Canevari S
    Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
    Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
    Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin.
    Battelli MG; Bolognesi A; Olivieri F; Polito L; Stirpe F
    J Drug Target; 1998; 5(3):181-91. PubMed ID: 9606008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1).
    Pfeifer W; Levi E; Petrogiannis-Haliotis T; Lehmann L; Wang Z; Kadin ME
    Am J Pathol; 1999 Oct; 155(4):1353-9. PubMed ID: 10514417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
    Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
    Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.
    Tazzari PL; Polito L; Bolognesi A; Pistillo MP; Capanni P; Palmisano GL; Lemoli RM; Curti A; Biancone L; Camussi G; Conte R; Ferrara GB; Stirpe F
    J Immunol; 2001 Oct; 167(8):4222-9. PubMed ID: 11591743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
    Flavell DJ; Boehm DA; Noss A; Flavell SU
    Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
    Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
    Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.